Hong Kong
· Delayed Price · Currency is HKD Akeso Company Description
Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes antibody drugs.
The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) cancer, ESCC, hepatocellular carcinoma (HCC), small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC), pancreatic cancer, and solid tumors; and AK112, a PD-1/VEGF bi-specific antibody to treat NSCLC, triple-negative breast cancer (TNBC), head and neck cancer, HCC, colorectal and ovarian cancer, and solid tumors.
It is also developing AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, GC, GEJ, ESCC, HNSCC, CRC, TNBC, and solid tumors/lymphoma; AK105, a PD-1 monoclonal antibody to treat classic Hodgkin’s lymphoma (R/R cHL), NSCLC, NPC, HCC, SCLC, thyroid cancer, mesothelioma and thymic cancer, ESCC, UC, GC, GEJ, cholangiocarcinoma, neuroendocrine tumor, and mismatch repair deficient solid tumor; AK119, a CD73 monoclonal antibody for treating solid tumors and NSCLC; and AK109, a VEGFR-2 monoclonal antibody to treat GC, GEJ, NSCLC, HCC, and solid tumors.
In addition, the company develops AK102, a PCSK9 monoclonal antibody to treat hypercholesterolemia and mixed hyperlipidemia; AK101, an IL-12/IL-23 monoclonal antibody to treat moderate-to-severe psoriasis and ulcerative colitis; AK111, an IL-17 monoclonal antibody to treat moderate-to-severe psoriasis and ankylosing spondylitis; and AK120, an IL-4R monoclonal antibody to treat moderate-to-severe atopic dermatitis.
Further, its preclinical product includes AK127, a TIGIT monoclonal antibody to treat solid tumors; and AK115, a NGF monoclonal antibody.
The company has collaboration agreements with Pfizer Pharmaceuticals; AstraZeneca Pharmaceuticals; Summit Therapeutics Inc.; and Shenzhen Chipscreen Biosciences Co., Ltd. Akeso, Inc. was founded in 2012 and is headquartered in Zhongshan, the People’s Republic of China.
| Country | Cayman Islands |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 2,778 |
| CEO | Yu Xia |
Contact Details
Address: No. 6, Shennong Road Zhongshan, 528437 China | |
| Phone | 86 76 0898 73998 |
| Website | akesobio.com |
Stock Details
| Ticker Symbol | 9926 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | KYG0146B1032 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Yu Xia Ph.D. | Founder, Chief Executive Officer, President and Chairwoman |
| Dr. Baiyong Li Ph.D. | Co-Founder, Executive Vice President, CSO and Executive Director |
| Zhongmin Wang Ph.D. | Co-Founder, Senior Vice President and Executive Director |
| Dr. Peng Zhang Ph.D. | Co-Founder, Senior Vice President and Executive Director |
| Dr. Bing C. Wang M.B.A., Ph.D. | Chief Financial Officer |
| Dr. Xinfeng Zhang | Senior Vice President |
| Wenjun Shi | Senior Vice President |
| Dr. Mingxiu Hu Ph.D. | Senior Vice President |
| Dr. Charlie Zhang Ph.D. | Senior Vice President |
| Dr. Jing Min Ph.D. | Senior Vice President |